Cabaletta Bio, Inc.

NasdaqGS:CABA

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

United States

Market Cap

USD 141.21 M

Share Price

USD 1.57

Avg Daily Volume

1,378,758

Change (1 day)

-7.65%

Change (1 year)

-78.61%

Change (YTD)

-30.84%

Cabaletta Bio, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025

Cabaletta Bio, Inc. Free Cash Flow is NA for the Trailing 12 Months (TTM) ending March 31, 2025. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Cabaletta Bio, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -66.05 M, a 35.16% change year over year.
Cabaletta Bio, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -48.87 M, a 23.82% change year over year.
Cabaletta Bio, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -39.46 M, a 27.24% change year over year.
Cabaletta Bio, Inc. Free Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -31.02 M, a 59.46% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Free Cash Flow	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities

NasdaqGS: CABA

Cabaletta Bio, Inc.

CEO	Dr. Steven A. Nichtberger M.D.
IPO Date	Oct. 25, 2019
Location	United States
Headquarters	2929 Arch Street
Employees	161
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.